FDA approves Saxenda® for the treatment of obesity in adolescents aged 12-17

Author's Avatar
Dec 05, 2020
Article's Main Image

Saxenda® (liraglutide) injection 3 mg becomes the first FDA-approved therapy to treat obesity in adolescents in more than a decade

PR Newswire